CLDX - Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.
Perryville III Building
Suite 220 53 Frontage Road
Hampton, NJ 08827
United States
908 200 7500
https://www.celldex.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 148
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Anthony S. Marucci M.B.A. | Founder, Pres, CEO & Director | 1.14M | 3.91M | 1962 |
| Dr. Tibor Keler | Founder, Chief Scientific Officer & Exec. VP | 739.03k | 575.74k | 1959 |
| Mr. Sam Martin | Sr. VP, CFO, Sec. & Treasurer | 617.26k | 634.9k | 1971 |
| Dr. Margo Heath-Chiozzi M.D. | Sr. VP of Regulatory Affairs | 614.12k | N/A | 1957 |
| Dr. Diane C. Young M.D. | Sr. VP & Chief Medical Officer | 643.5k | 2.04M | 1957 |
| Prof. Joseph P. Schlessinger Ph.D. | Co-Founder & Member of Scientific Advisory Board | N/A | N/A | 1945 |
| Ms. Sarah Cavanaugh | Sr. VP of Corp. Affairs & Admin. | N/A | N/A | 1975 |
| Patrick Till | Sr. Director of Investor Relations & Corp. Communications | N/A | N/A | N/A |
| Mr. Freddy A. Jimenez Esq. | Sr. VP & Gen. Counsel | N/A | N/A | 1969 |
| Dr. Ronald A. Pepin | Chief Bus. Officer & Sr. VP | N/A | N/A | 1956 |
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Corporate governance
Celldex Therapeutics, Inc.’s ISS governance QualityScore as of 1 June 2023 is 1. The pillar scores are Audit: 1; Board: 2; Shareholder rights: 1; Compensation: 5.
